Fulcrum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	26.66	36.19	36.5	58.14	97.81	73.89	0.41
Short-Term Investments	210.66	167.82	182.75	55.86	0	0	0
Cash & Cash Equivalents	237.31	204.01	219.25	114.01	97.81	73.89	0.41
Cash Growth	16.32%	-6.95%	92.32%	16.56%	32.37%	18054.55%	-
Receivables	0.54	0.23	3.64	2.53	0	0	0
Other Current Assets	4.35	3.28	3.11	2.97	2.28	0.21	0.93
Total Current Assets	242.2	207.52	226	119.51	100.08	74.1	1.34
Property, Plant & Equipment	12.39	15.97	7.37	8.4	9.21	10.55	2.94
Other Long-Term Assets	3.1	3.2	1.63	1.67	1.15	1.13	0.06
Total Long-Term Assets	15.5	19.17	9	10.07	10.36	11.68	3
Total Assets	257.69	226.69	235	129.58	110.44	85.77	4.34
Accounts Payable	2.76	3.64	4.79	4.08	2.19	1.26	1.67
Deferred Revenue	0	0.93	4.71	17.88	10	0	0
Current Debt	2.19	2.6	0	0	0	0	0
Other Current Liabilities	8.73	9.55	9.7	4.77	-0.05	2.97	1.11
Total Current Liabilities	13.68	16.73	19.2	26.73	12.14	4.23	2.79
Long-Term Debt	8.63	10.82	0	0	0	0	0
Other Long-Term Liabilities	0.2	0.2	4.26	7.67	11.15	5.54	0.23
Total Long-Term Liabilities	8.83	11.02	4.26	7.67	11.15	5.54	0.23
Total Liabilities	22.5	27.74	23.46	34.4	23.29	9.77	3.02
Total Debt	10.82	13.42	0	0	0	0	0
Debt Growth	-19.38%	-	-	-	-	-	-
Retained Earnings	-509.67	-412.34	-302.47	-221.62	-150.8	-68.12	-35.54
Comprehensive Income	-0.14	-0.8	-0.4	-0	0	0	0
Shareholders' Equity	235.19	198.94	211.54	95.18	87.15	-63.67	-33.27
Net Cash / Debt	226.49	190.59	219.25	114.01	97.81	73.89	0.41
Net Cash / Debt Growth	18.84%	-13.07%	92.32%	16.56%	32.37%	18054.55%	-
Net Cash Per Share	3.69	4.24	6.20	4.50	8.85	58.78	0.57
Working Capital	228.52	190.79	206.8	92.79	87.94	69.87	-1.45
Book Value Per Share	3.84	4.42	5.98	3.75	7.89	-50.65	-46.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).